Prosecution Insights
Last updated: November 20, 2026
Application No. 18/527,005

COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Dec 01, 2023
Priority
Aug 30, 2019 — CIP of PCTUS2019048962 +5 more
Examiner
KELLY, ROBERT M
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Yale University
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
705 granted / 953 resolved
+14.0% vs TC avg
Strong +24% interview lift
Without
With
+24.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
51 currently pending
Career history
991
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
18.9%
-21.1% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
43.2%
+3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 953 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendment and response to restriction requirement of 9/24/26 are entered. Claim 30 is amended. Claims 1, 6-7, 10-12, 14-16, 18-20, 23-24, 27-28, 33, 39, and 42 are canceled. Claims 46-64 are newly presented. Claims 30 and 46-64 are pending. Election/Restrictions The species elections are withdrawn. As such, the claims are considered for all species. Formalities The IDS filings of 5/3/24 and 9/24/26 and the references cited therein have been considered. A signed copy of each is provided herewith. The drawings of 12/1/23 are accepted. The specification of 12/1/23 is accepted. Applicant’s priority is noted to be: PNG media_image1.png 114 864 media_image1.png Greyscale Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 30, 46-53, and 55-62 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. MPEP 2163.02 The courts have described the essential question to be addressed in a description requirement issue in a variety of ways. An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, the inventor was in possession of the invention, and that the invention, in that context, is whatever is now claimed. The test for sufficiency of support in a parent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had possession at that time of the later claimed subject matter." Ralston Purina Co. v. Far-Mar-Co., Inc., 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting In re Kaslow, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)).[AltContent: rect] Whenever the issue arises, the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, inventor was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). An applicant shows that the inventor was in possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Lockwood v. Am. Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997). Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the inventor was in possession of the claimed invention. See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998); Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997); Amgen, Inc. v. Chugai Pharm., 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it"). The claims are generic to treating cancer with single stranded DNA, as emphasized by depending claim 53. The specification provides antecedent basis for cargos which are single stranded nucleic acids (e.g., p. 4, paragraph 4), as well as ssDNA (e.g., p. 8, paragraph 1). ssDNA is actually disclosed in the examples (e.g., Example 11), but is limited to a determination of tissues to which the composition is delivered (e.g., Id.). I.e., there is no therapy taught for single stranded DNAs. The art fails to disclose a single embodiment of a single type of cancer which is treated by a single stranded DNA. In fact, it appears that the Art is focused on the development of single stranded DNA in the process of chemotherapy of cancer cells and DNA damage repair (e.g., O’Connor (2015) “Targeting the DNA Damage Response in Cancer”, Molecular Cell, 60: 547-60, ABSTRACT). Given the absence of information in the art that an administered ssDNA could be administered and treat any form of cancer, and lack of description by Applicant as to what is required of the ssDNA to effect such therapy, the Artisan would not have understood Applicant to have been in possession of the invention as presently claimed. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 30, 46-55, 58, and 60-62 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. MPEP 2163.02 The courts have described the essential question to be addressed in a description requirement issue in a variety of ways. An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, the inventor was in possession of the invention, and that the invention, in that context, is whatever is now claimed. The test for sufficiency of support in a parent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had possession at that time of the later claimed subject matter." Ralston Purina Co. v. Far-Mar-Co., Inc., 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting In re Kaslow, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)).[AltContent: rect] Whenever the issue arises, the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, inventor was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). An applicant shows that the inventor was in possession of the claimed invention by describing the claimed invention with all of its limitations using such descriptive means as words, structures, figures, diagrams, and formulas that fully set forth the claimed invention. Lockwood v. Am. Airlines, Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (Fed. Cir. 1997). Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the inventor was in possession of the claimed invention. See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998); Regents of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997); Amgen, Inc. v. Chugai Pharm., 927 F.2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it"). As seen by Claim 58, the claims are generic for treating leukemia. The specification provides broad antecedent basis demonstrating an envisioning of treatment of leukemia (e.g., p. 108, penultimate paragraph), but fails to provide a single embodiment of what nucleic acid cargo is required to treat leukemia and how to administer it. The Art fails to provide an example of a single embodiment of leukemia treatment where the nucleic acid is delivered to the leukemia cell as required by the claims. However, the first gene therapy for a leukemia was approved by the FDA in 2017 (Rob Stein (2017) “FDA Approves First Gene Therapy for Leukemia”, published by NPR at CAR-T Therapy For Leukemia Wins FDA Approval : Shots - Health News : NPR, NPR, Washington, DC, 13 pages as printed). However, this therapy is CAR-T cell therapy for leukemia, and thus, the cells that are transfected are not the leukemia cells, they are T cells that are not leukemic. Additionally, because the compositions target all cells, similar to 3E10, they would not be predicted to reach the leukemia cells themselves, as other cells in the body would be met with the composition first. Given the lack of description by Applicant, lack of demonstration in the Art, and wide variety of forms of nucleic acid which are encompassed, The Artisan would not have understood Applicant to have been in possession of treatment of leukemia. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. MPEP 1504.06 There are generally two types of double patenting rejections. One is the same invention type or "statutory" double patenting rejection based on 35 U.S.C. 171 which states in the singular that an inventor may obtain "a patent." The second is the "nonstatutory" double patenting rejection based on a judicially created doctrine grounded in public policy and which is primarily intended to prevent prolongation of the patent term by prohibiting claims in a second patent not patentably distinct from claims in a first patent. The doctrine of nonstatutory double patenting also seeks to prevent the possibility of multiple suits against an accused infringer by different assignees of patents claiming patentably indistinct variations of the same invention. In re Van Ornum, 686 F.2d 937, 944-48, 214 USPQ 761, 767-70 (CCPA 1982). The submission of a terminal disclaimer in compliance with 37 CFR 1.321(b) to overcome a double patenting rejection ensures that a patent owner with multiple patents claiming obvious variations of one invention retains all those patents or sells them as a group. Van Ornum, 686 F.2d at 944-45, 214 USPQ at 767. Nonstatutory double patenting includes rejections based on anticipation, a one-way determination of "obviousness," or a two-way determination of "obviousness." It is important to note that the "obviousness" analysis for nonstatutory double patenting is "similar to, but not necessarily the same as, that undertaken under 35 U.S.C. 103." In re Braat, 937 F.2d 589, 592-93, 19 USPQ2d 1289, 1292 (Fed. Cir. 1991) (citing In re Longi, 759 F.2d 887, 892 n.4, 225 USPQ 645, 648 n.4 (Fed. Cir. 1985)); Geneva Pharmaceuticals, 349 F.3d 1373, 1378 n.1, 68 USPQ2d 1865, 1869 n.1 (Fed Cir. 2003). In addition, nonstatutory double patenting also includes rejections based on the equitable principle against permitting an unjustified timewise extension of patent rights. See In re Schneller, 397 F.2d 350, 158 USPQ 210 (CCPA 1968); see also MPEP § 804, subsection II.B.6. 12,485,180 Claims 30, 46-52, 54, and 60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Wu, et al. (2011) “Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors” Cancer Immunology and Immunotherapy, 60: 1085-96. Claim 30: Claim 1 teaches delivering a nucleic acid cargo to a cell, by contacting the cell with a composition comprising acomplex of an antibody/antigen-binding fragment thereof comprising a VH with SEQ ID NO: 16, 17 and 18, and a VL with SEQ ID NO:24, 25 and 26, complexed with a nucleic acid cargo of DNA, RNA, or plasmid, among others. Claim 46: Claim 3 teaches, e.g., mRNA. Claim 47: Claim 4 teaches a vector. Claim 48: Claim 5 teaches the expression control sequence operably linked. Claim 49: Claim 6 teaches a carrier DNA. Claim 50: Claim 7 teaches a non-coding DNA. Claim 51: Claim 8 teaches administration to a subject and in vivo contacting. Claim 52: Claim 9 teaches an oligonucleotide ligand. Claim 60: Claim 1 teaches it may be humanized. However, the patent does not claim the use of poly(I:C) oligonucleotides, and treating cancer cells. On the other hand, Wu teaches the use of poly(I:C) with PEI to increase transfection efficiency, and treats tumor bearing mice (e.g., ABSTRACT). With regard to Claim 54: poly(I:C) is a Rig-I ligand. Thus, in light of Wu, it would be obvious to modify the patent to utilize the poly(I:C) of Wu, to obtain the invention. The Artisan would do so to treat the mice. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 55-56, and 60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Fewell, et al. (2005) “Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer”, Journal of Controlled Release, 109: 288-98. As shown above, the patent teaches various aspects, but does not teach treatment of breast cancer. On the other hand, Fewell teaches the delivery of DNA encoding IL-12 by injection into the tumor (e.g., p. 290, section 2.4). Thus, at the time of invention, it would have been obvious to modify invention of the patent and utilize the plasmids of Fewell for delivery into the breast cancer. The Artisan would do so to treat the cancer. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 55, 57, and 60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Pecot, et al. (2014) “Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs”, Molecular Cancer Therapeutics, 13(12): 1-10. As shown above, the various aspects are claimed, but the treatment of colon cancer and use of siRNA is not claimed. On the other hand, Pecot teaches the administration of siRNAs to KRAS in a colon cancer model mouse (OF2, col. 2), which treats the same (e.g., ABSTRACT). Thus, at the time of invention, it would have been obvious to modify the patent and utilize the siRNAs of Pecot, to treat colon cancer models in mice. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 55-56, 60 and 64 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Yu, et al. (March 2018) “Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer”, Molecular Therapy: Nucleic Acids, 10: 317-30. As shown above, the various aspects are claimed, but the treatment of breast cancer and use of siRNA is not claimed. On the other hand, Yu teaches siRNA to EGFR, in treating breast cancer cells in mice (e.g., p. 329, col. 1, paragraph 2. Thus, at the time of invention, it would have been obvious to modify the patent and utilize the siRNAs of Yu, to treat breast cancer models in mice. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 55-56, 60 and 64 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Ahmadzada, et al. (January 2018) “Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer”, Biophysical Reviews, 10: 69-86. As shown above, the various aspects are claimed, but the treatment of breast cancer and use of siRNA is not claimed. On the other hand, Ahamdzada teaches it is known to utilize siRNAs in treatment of breast cancer in animal models (e.g., p. 76, paragraph bridging columns; p. 77, paragraph bridging columns; pp. 77-81, paragraph bridging columns; pp. 81-82, paragraph bridging columns). Thus, at the time of invention, it would have been obvious to modify the patent and utilize the siRNAs of Ahamdzada, to treat breast cancer models in animal models. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 55-56, 60 and 63 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Liu, et al. (January 2018) “Combination Immunotherapy of MUC1 mRNA Nano-Vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer”, Molecular Therapy, 26(1): 45-55. As shown above, the various aspects are claimed, but the treatment of breast cancer and use of mRNA is not claimed. On the other hand, Liu teaches treatment of triple negative breast cancer with a combination of therapy including delivery of an mRNA encoding MUC1 (e.g., ABSTRACT; p. 48-49). Thus, at the time of invention, it would have been obvious to modify the patent and utilize the siRNAs of Liu in the combination therapy, to treat breast cancer models in animal models. The Artisan would expect success, as the components are utilized for art-recognized purposes. Claims 30, 46-52, 54, and 60 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 of U.S. Patent No. 12,485,180 in view of Karjoo, et al. (2016) “Progress and problems with the use of suicide genes for targeted cancer therapy”, Advanced Drug Delivery Reviews, 99: 113-128. As shown above, the various aspects are claimed, however, the aspect of treatment of osteosarcoma by delivery of a suicide gene therapy is not taught. On the other hand, Karjoo teaches that osteosarcoma can be treated by suicide gene therapy in vitro (e.g., Table 1). Thus, in light of Karjoo, it would be obvious to modify the patent to utilize suicide gene therapy to treat osteosarcoma in vitro. The Artisan would do so to treat the cancer. The Artisan would expect success, as the components are utilized for art-recognized purposes. 11,850,284 Claims 30, 46, 49, and 60-63 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 11,850,284 in view of Liu, et al. (January 2018) “Combination Immunotherapy of MUC1 mRNA Nano-Vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer”, Molecular Therapy, 26(1): 45-55. Claim 30: the patent teaches the same antibody/fragment structure with the VH CDRs of SEQ ID NOs: 16-18 and VL CDRs of SEQ ID NOs: 24-26, complexed with an mRNA (e.g., Claim 1). Claim 46: the patent teaches mRNA (e.g., Claim 1). Claim 49: as it is an mRNA, it necessarily has the proper region for initiation of translation. Claim 60: humanized is taught (e.g., Claim 6). Claim 61: Claim 2 teaches the same identities. Claim 62: Claim 4 teaches the same identities. As shown above, the various aspects are claimed, but the treatment of breast cancer and use of mRNA is not claimed. On the other hand, Liu teaches treatment of triple negative breast cancer with a combination of therapy including delivery of an mRNA encoding MUC1 (e.g., ABSTRACT; p. 48-49). Thus, at the time of invention, it would have been obvious to modify the patent and utilize the siRNAs of Liu in the combination therapy, to treat breast cancer models in animal models. The Artisan would expect success, as the components are utilized for art-recognized purposes. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M KELLY whose telephone number is (571)272-0729. The examiner can normally be reached M-F: 8a-5p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ROBERT M. KELLY Examiner Art Unit 1638 /ROBERT M KELLY/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Dec 01, 2023
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799456
Galectin-9 Specific Binding Agents for Use in Treating Cancer
3y 9m to grant Granted Nov 17, 2026
Patent 12758769
Transdermal Optogenetic Peripheral Nerve Stimulation
3y 11m to grant Granted Oct 13, 2026
Patent 12760330
COMPOSITIONS AND METHODS FOR TREATING CEP290 ASSOCIATED DISEASE
3y 8m to grant Granted Oct 13, 2026
Patent 12747425
EX VIVO PROLIFERATION OF EPITHELIAL CELLS
3y 4m to grant Granted Sep 29, 2026
Patent 12747279
CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
3y 7m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
98%
With Interview (+24.4%)
2y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 953 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month